September 2005
Worldwide Biotech;Sep2005, Vol. 17 Issue 9, p6
Trade Publication
Reveals the plans of Valeant Pharmaceuticals International to initiate the development of Viramidine, a nucleoside (guanosine) analog in Japan. Status of the company's clinical trials for Viramidine; Appointment of Masao Omata, professor and chair, Department of Gastroenterology at the University of Tokyo, at the company's hepatitis C Japanese advisory board; Prevalence of hepatitis C infection in Japan.


Related Articles

  • Valeant Pharmaceuticals Reports Good Hep C Test Results in Trial. Reed, Vita // Orange County Business Journal;12/1/2008, Vol. 31 Issue 48, p19 

    The article reports on the middle-stage clinical trial results for a hepatitis C drug candidate initiated by Valeant Pharmaceuticals in Orange County, California. Valeant revealed that it was gong to license the rights to taribavirin as part of a strategic shift away from drugs to treat...

  • Valeant Eyes Developing Drugs, Acquisitions. Reed, Vita // Orange County Business Journal;9/25/2006, Vol. 29 Issue 39, p3 

    The article reports on the plan of Costa Mesa-based drug maker Valeant Pharmaceuticals International of making one more trial for its liver disease drug, Viramidine in 2006. According to its CEO Timothy Tyson, regardless of how Viramidine fares in a final test, Valeant plans to continue focusing...

  • EASL Roundup.  // BioWorld Today;4/27/2009, Vol. 20 Issue 79, p3 

    The article reports on the results of an analysis of Phase IIb trial from Valeant Pharmaceuticals Inc. regarding taribavirin, a prodrug of ribavirin, with a pegylated interferon. The drug showed comparable reductions in viral load for weight-based doses of the drugs similar to data observed in...

  • Valeant Vows Weak Results Won't Kill Drug. Reed, Vita // Orange County Business Journal;3/27/2006, Vol. 29 Issue 13, p3 

    The article reports that drug maker Valeant Pharmaceuticals International (VPI) company is planning to move toward the registration of the hepatitis C treatment in late 2007. The announcement was made by CEO of VPI Timothy Tyson in a conference with investors and analysts about the clinical...

  • Cervical cancer vaccine shows promise. Chernin, Tammy // Drug Topics;11/7/2005, Vol. 149 Issue 21, p17 

    Reports developments related to drug development in the U.S. Capability of Merck & Co. Inc.'s Gardasil, a human papillomavirus vaccine, in preventing cervical cancer; Efficacy of the endothelin A receptor antagonist of Speedel Group; Schedule of the phase III clinical trial of Valeant...

  • Other Cancers.  // PharmaWatch: Cancer;Apr2007, Vol. 6 Issue 4, p9 

    The article offers news briefs regarding different drugs for cancer. The results of a phase II clinical trial that was published in "Clinical Cancer Research" shows that the combination Avastin (bevacizumad) from Genentech/Roche and Comptosar (irinotecan) from Pfizer, shows tumor shrinkage of at...

  • Pharma: Clinic Roundup.  // BioWorld Today;11/27/2012, Vol. 23 Issue 229, p8 

    The article reports that the results from two clinical trials of efinaconazole by Valeant Pharmaceuticals International Inc. have been published in the "Journal of the American Academy of Dermatology."

  • One More Viramidine Trial, Then Decision Time for Valeant. Reed, Vita // Orange County Business Journal;9/18/2006, Vol. 29 Issue 38, p5 

    The article reports on the interim clinical trial of Viramidine in considering higher doses in the treatment of hepatitis C drug from Valeant Pharmaceuticals in Costa Mesa, California. The drug maker is hopeful in the replacement of ribavirin, after failure in tow recent late-stage clinical...

  • San Antonio Breast Cancer Symposium.  // BioWorld Today;12/10/2012, Vol. 23 Issue 238, p7 

    The article reports on the positive results obtained by Valeant Pharmaceuticals International Inc. from a Phase III study of Halaven or eribulin.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics